Newer markers may improve on PSA's shortcomings

Q What is the current state of prostate cancer markers?With prostate cancer, we are fortunate in that it has the very best markeror combination of markers for any cancer that I'm aware of, short of skincancer where visual markers are quite good. PSA's performance for predictinglocalized prostate cancer probably exceeds the performance of other cancermarkers, such as CA125 for ovarian cancer, CEA for colon cancer, and someof the genetic markers for breast cancer.

Related Videos

Related Content

Advertisement

September 10th 2024

Data show short-term benefit of certain hormonal treatments for GSM

Hannah Clarke

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

August 27th 2024

Topical sildenafil cream found safe, tolerable in female sexual arousal disorder

Hannah Clarke

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

February 27th 2024

FDA approves cefepime/enmetazobactam for complicated UTI

Hannah Clarke

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

February 24th 2024

Information and Guidance on the Adoption of Surgical Innovation and Technology in Urogynecology

American Urogynecologic Society

The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.

Related Content

Advertisement

September 10th 2024

Data show short-term benefit of certain hormonal treatments for GSM

Hannah Clarke

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

August 27th 2024

Topical sildenafil cream found safe, tolerable in female sexual arousal disorder

Hannah Clarke

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

February 27th 2024

FDA approves cefepime/enmetazobactam for complicated UTI

Hannah Clarke

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

February 24th 2024

Information and Guidance on the Adoption of Surgical Innovation and Technology in Urogynecology

American Urogynecologic Society

The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.